IInsmed focuses on developing and delivering therapies for serious and rare diseases. Its products come from a pipeline of clinical trials and approved treatments, sold to patients in global markets with offices in Bridgewater, NJ, Europe, and Japan. The company’s work combines research and development, regulatory approvals, and commercialization to bring therapies from discovery to patients. Insmed differentiates itself by addressing unmet medical needs in rare diseases and maintaining a global infrastructure that supports development, approval, and patient access. The goal is to improve patient outcomes by providing effective treatments for conditions with limited existing options.
Work here?Claim your company
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Bridgewater Township, New Jersey
Founded
1988
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$3.4B
Above
Industry Average
Funded Over
10 Rounds
Insmed CFO Sara Bonstein to step down October 30. The Distributed 4 hours ago 72 Insmed Incorporated said in a filing that Chief Financial Officer Sara Bonstein will step down from her role on October 30, 2026, after nearly seven years with the company. Bonstein will remain CFO through the company's third-quarter 2026 earnings report and will participate in the related conference call on Thursday, October 29, 2026, before her departure takes effect. Insmed said it has started a search for its next CFO, partnering with an executive search firm to fill the role. Will Lewis, Chair and Chief Executive Officer, credited Bonstein with overseeing the company's finance organization during a period in which Insmed raised more than $4.2 billion in capital. Lewis said the company is now positioned to reach cash flow positivity next year. Bonstein said serving as CFO was a privilege and cited confidence in Insmed's future, pointing to the launch of BRINSUPRI and the company's pipeline as reasons for her outlook. The company stated that Bonstein's transition is not related to any disagreement with Insmed over accounting practices, financial statements, internal controls, or operations. Insmed reaffirmed its full-year 2026 financial guidance, projecting revenue of $1.25 billion to $1.40 billion for BRINSUPRI (brensocatib) and $450 million to $470 million for ARIKAYCE (amikacin liposome inhalation suspension). The company also announced it will release third-quarter 2026 financial results on Thursday, October 29, 2026. Management will host a conference call for investors at 8:00 a.m. ET that day to discuss the results and provide a business update, with the call also webcast on the company's website. A replay will be available through November 5, 2026, and an archived webcast will remain posted under the Investor Relations section of Insmed's website for 90 days. The post Insmed CFO Sara Bonstein to step down October 30 appeared first on the Distributed. BitRss shares this Content always with License. Screenshot generated in real time with SneakPeek Suite
Somerset County Business Partnership announces 2026 Business of the Year Award recipients. By Carly Mac Manus Published September 28, 2026 at 2:32 PM SOMERVILLE, NJ - The Somerset County Business Partnership has announced Alpine Business Systems, R&J Strategic Communications and Insmed as its 2026 Business of the Year Award recipients. The three organizations will be recognized at SCBP's 2026 Annual Meeting on Monday, Dec. 14 from 11:30 a.m. to 2 p.m. at The Palace in Somerset. As SCBP's largest stakeholder gathering of the year, the Annual Meeting brings together business leaders, community partners and decision-makers from across Somerset County to celebrate the past year and look ahead to 2027. SCBP will also announce its Top 40 Under 40 Class of 2026 during the event. Get local news you can trust in your inbox. "The Somerset County Business Partnership is proud to recognize this year's Business of the Year honorees for their outstanding leadership, innovation, and commitment to strengthening our regional economy. These organizations represent the very best of Somerset County's business community, demonstrating excellence not only through their success, but through their dedication to their employees, customers, and the communities they serve. We congratulate each of our winners and thank them for helping make Somerset County one of the most vibrant places to live, work, and do busines,." said Chris Edwards, President and CEO of the Somerset County Business Partnership. Alpine Business Systems For more than 38 years, Alpine Business Systems has focused on using technology to improve the lives of its clients, employees and community. "All of us at Alpine are honored to receive this award," the company shared. "We thank the Partnership for this award and are grateful to its staff and members for giving us the opportunity to personally communicate the potential for technology to positively impact people's lives and businesses. We look forward to working with the Partnership for the next 38 years to help businesses realize technology's potential, always keeping people at the center of what we do." R&J Strategic Communications The recognition comes as R&J Strategic Communications celebrates its 40th anniversary and 20 years as an SCBP member. "This recognition comes at a meaningful time for R&J as we celebrate our 40th anniversary and 20 years as a member of the Somerset County Business Partnership," said Scott Marioni, president of R&J. "Our mission has always been to make a difference for our clients, our team and our communities, and the SCBP has been an important partner in helping us live that mission here in Somerset County." R&J is a full-service integrated digital marketing and public relations agency specializing in commercial real estate, healthcare, human services and nonprofit communications. Insmed, a global biopharmaceutical company with a presence in Somerset County, is also among this year's honorees. "It is an honor to be named the Somerset County Business Partnership's Business of the Year," said Nicole Schaeffer, Chief People Strategy Officer of Insmed. "This award is a reflection of the passion, collaboration and purpose that our talented employees bring to their work every day, as well as the strong ties we have built within Somerset County over the years. Just as we strive to transform the lives of patients with serious and rare diseases, we also feel a deep responsibility to make a positive impact in the communities where we live and work." 2026 Annual Meeting The Somerset County Business Partnership Annual Meeting will take place Monday, Dec. 14 from 11:30 a.m. to 2 p.m. at The Palace in Somerset, New Jersey. Registration is now open, with sponsorship and advertising opportunities also available. Registration: https://members.scbp.org/ap/Events/Register/oXFD0vOF6C2CB Sponsorship Opportunities: https://www.scbp.org/annualmeeting-sponsorships/ About the Somerset County Business Partnership The Somerset County Business Partnership connects businesses, creates opportunities for growth and works to strengthen Somerset County's business community through networking, education, resources, advocacy and strategic partnerships. Get More TAPinto Local News on Google
Insmed to present at September 2026 investor conferences. Aug 26, 2026, 07:00 ET BRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: * 12th Annual Cantor Fitzgerald Global Healthcare Conference in New York City on Wednesday, September 9, 2026, at 8:00 a.m. ET. * 24th Annual Morgan Stanley Global Healthcare Conference in New York City on Monday, September 14, 2026, at 2:35 p.m. ET. These events will be webcasted live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events. About Insmed Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines - including two approved therapies to treat chronic, debilitating lung diseases - as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates. Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more or follow us on LinkedIn, Instagram, YouTube, and X. Claire Mulhearn Vice President, Corporate Communications [email protected] SOURCE Insmed Incorporated
Insmed's stock trades at 25.3 times sales despite falling 37% from its 52-week high, as revenue nearly tripled to $1.1 billion over the past twelve months. The premium reflects management's raised peak-sales estimate of over $14 billion across three lead programmes. BRINSUPRI, the company's bronchiectasis drug, generated $309.2 million in its third full quarter, up 49% sequentially. Management raised full-year BRINSUPRI guidance to between $1.25 billion and $1.4 billion. However, more than $6 billion of the peak estimate depends on TPIP, an inhaled treatment for pulmonary arterial hypertension, which is still in Phase III trials. The company ended June with $1.2 billion in cash, which management says will fund operations to cash flow positivity in 2027.
Insmed's share price surged 33.86% on Thursday to close at $132.55 after the biopharmaceutical company nearly quadrupled its revenues in the second quarter. Total revenues soared 296% to $425.5 million from $107.4 million year-on-year, driven primarily by Brinsupri, its non-cystic fibrosis bronchiectasis treatment, which contributed $309.2 million. The company's lung disease treatment Arikayce added $116.3 million in revenues, up 8% year-on-year. The strong performance helped slash net loss by 96% to $13.2 million from $321.7 million in the same period last year. Insmed raised its full-year revenue guidance to between $1.25 billion and $1.4 billion, representing growth of 624% to 710.6% year-on-year. Investors will be watching whether Brinsupri can sustain momentum whilst the company awaits regulatory decisions for brensocatib in Japan in the second half of 2026.
Find jobs on Simplify and start your career today
Industries
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Bridgewater Township, New Jersey
Founded
1988
Find jobs on Simplify and start your career today